Latest Securities Purchase Plan News

Lowell Resources Fund plans to raise about A$10 million through a wholesale placement of nearly 5 million new units at A$2.01 each, matching its recent distribution reinvestment plan price. A Securities Purchase Plan at the same price will follow, aiming to extend the capital raise to retail unitholders.

Enlitic slashed its net operating cash outflow by 76% in Q2 FY26 and secured binding commitments for a A$15 million conditional placement alongside convertible note conversions, positioning the company with a pro forma cash balance of about A$18 million and a debt-free balance sheet.

X2M Connect has secured $2 million in a placement to boost its data centre and AI energy management platform, with a fully underwritten $1 million Securities Purchase Plan to follow. The capital raise supports sensor integration, platform enhancements, and battery energy systems aimed at cutting data centre precinct energy costs by up to 20%.

Enlitic plans a A$15 million capital raise through a conditional placement and a targeted A$1 million security purchase plan, alongside a 10-to-1 share consolidation, all subject to shareholder approval and ASX waivers.

Right Resources Limited has raised A$2.7 million through a placement anchored by major shareholders, including directors, to fund drilling and exploration across its Tumbarumba and New England projects.

Enlitic has locked in binding commitments for a conditional A$15 million capital raise alongside a convertible note conversion, setting the stage for a clearer path to cashflow break-even and accelerated rollout of its SaaS platform.

Microba Life Sciences is targeting a $6 million capital raise through a $1 million Securities Purchase Plan and a $5 million Placement, both subject to shareholder approval. The funds aim to accelerate diagnostics growth and develop a new testing product.

EPX Limited has locked in a $3 million senior secured revolving loan note facility with Partners for Growth, providing capital to seize new revenue opportunities and support working capital over the next three years.

Botanix Pharmaceuticals reported a 5% rise in Sofdra prescriptions in Q3 FY26 despite a dip in net revenue due to insurance deductible resets, strengthened by a $45 million capital raise and a new API supply deal with Piramal.

Oneview Healthcare boosted its cash reserves to €10.3 million by completing a significant capital raise and is progressing its AI-powered Care Assistant, Ovie, with pilot deployments planned for 2026.

Oneview Healthcare has secured A$12.3 million from its placement and security purchase plan, though the SPP fell well short of its A$2 million target. The company will now seek shareholder approval for the final tranche of its A$19 million raise at the September AGM.

Oneview Healthcare PLC has launched a Security Purchase Plan (SPP) to raise up to A$2 million, following a recent A$19 million placement. The SPP offers eligible shareholders discounted shares to support AI development and customer deployments.